Aglafoline
Aglafoline inhibits PAF-induced platelet aggregation, with an IC50 value of 50 μM.
Product Specifications
CAS Number
143901-35-3
Product Name Alternative
Aglafolin; Rocaglamide U; (-) -Methyl rocaglate
UNSPSC
12352005
Target
Potassium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Aglafoline.html
Concentration
10mM
Purity
98.46
Solubility
DMSO : 21.43 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic)
Smiles
O=C([C@H]([C@H]1C2=CC=CC=C2)[C@@H](O)[C@]3(O)[C@@]1(C4=CC=C(OC)C=C4)OC5=CC(OC)=CC(OC)=C35)OC
Molecular Formula
C28H28O8
Molecular Weight
492.52
References & Citations
[1]Ko FN, et al. PAF antagonism in vitro and in vivo by aglafoline from Aglaia elliptifolia Merr. Eur J Pharmacol. 1992 Jul 21;218 (1) :129-35.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MAPK13, Recombinant, Human, aa1-365, His-SUMO-Tag (Mitogen-activated Protein Kinase 13)
MAPK13, Recombinant, Human, aa1-365, His-SUMO-Tag (Mitogen-activated Protein Kinase 13)
MAPK13, Recombinant, Human, aa1-365, His-SUMO-Tag (Mitogen-activated Protein Kinase 13)
Integrin beta 3 Polyclonal Antibody Gold Conjugated
